First Edition, July 2009
Trainers’ Manual
This publication by UNAIDS, UNDP and the International Organisation for Migration examines various dimensions related to migration and HIV and AIDS.
Joint Action for Results
UNAIDS Outcome Framework: Business Case 2009–2011
Policy and Legal Opportunities for HIV Testing Services and Civil Society Engagement
Rural Development through decent work
Themes: Rural Policy Briefs
Participant Manual
October 2009
Since 2001, several Demographic and Health Surveys (DHS) include HIV
testing. For many countries, in particular in sub-Saharan Africa, DHS are
the only national source of data in general population. Several DHS collect
latitude and longitude of surveyed clusters but the sampling method is not
ap...propriate to derive local estimates: sample size is not large enough for a
direct spatial interpolation.
We developed a generic approach to map spatial regional trends of HIV
prevalence from DHS. We present how our results from Burkina Faso 2003
DHS shed new light on HIV epidemics.
more
29 Dec 2021. Comprehensive slideset updated regularly to include the latest data and guidance on best practices for COVID-19 diagnosis and prevention of COVID-19 transmission.
Estimated number of pregnant women, number with access to at least four antenatal care visits, and those delivering in hospital settings in the Americas, 2019...
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
The COVID-19 CARE pathway is a living tool to support health care workers visualize the current clinical and therapeutic recommendations to be considered in the care planning for patients with COVID-19.
The COVID-19 CARE pathway is aligned with the eighth version of the WHO Therapeutics and COVID...-19: living guideline published on the 14 January 2022 and the third version of the WHO COVID-19 Clinical management: living guidance published on the 23 November 2021.
more